# A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

> **NCT02382549** · EARLY_PHASE1 · TERMINATED · sponsor: **Craig L Slingluff, Jr** · enrollment: 8 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** BRAF inhibitor
- **BIOLOGICAL:** 6MHP
- **DRUG:** MEK inhibitor

## Key facts

- **NCT ID:** NCT02382549
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated because of slow accruals.
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382549, "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02382549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*